



EDUCATIONAL OBJECTIVE: Readers will advise their patients that the hypothesis that elevated homocysteine should be treated to reduce the risk of cardiovascular disease has neither been proved nor disproved

JOELLYN M. ABRAHAM, MD
Cardiovascular Medicine, Cleveland Clinic

LESLIE CHO, MD
Section Head, Preventive Cardiology
and Rehabilitation, and Director, Women's
Cardiovascular Center, Cleveland Clinic

The homocysteine hypothesis: Still relevant to the prevention and treatment of cardiovascular disease?

ABSTRACT

Although evidence suggests that the homocysteine hypothesis is still relevant as a predictor of cardiovascular risk, we cannot conclude that measuring the homocysteine level is useful in guiding treatment. Furthermore, studies of primary and secondary prevention show no evidence that taking folic acid or other B vitamins lowers the risk of cardiovascular events.

KEY POINTS

Factors that can cause the plasma homocysteine concentration to be high include deficiencies of vitamin B₆, vitamin B₁₂, and folic acid; renal insufficiency; and genetic variants in enzymes responsible for homocysteine metabolism.

Higher plasma homocysteine levels are associated with a higher risk of cardiovascular, cerebrovascular, and peripheral arterial disease.

Supplementation of B vitamins and folic acid can lower plasma homocysteine levels.

Randomized controlled trials of supplementation to prevent cardiovascular events and other adverse outcomes have had mostly negative results. However, most patients in these trials had normal baseline plasma homocysteine levels.

Needed are randomized trials to see if supplementation improves outcomes in patients with high homocysteine levels.

doi:10.3949/ccjm.77a.10036

PATIENTS OFTEN ASK primary care physicians and cardiologists about the measurement of biomarkers for cardiovascular disease and about the efficacy of preventive measures.

Although studies have shown that elevated homocysteine is a risk factor for cardiovascular and peripheral arterial disease¹⁻³ and that supplementation with folic acid, vitamin B₆, and vitamin B₁₂ lowers homocysteine levels,^{4,5} it is unclear whether such supplementation prevents cardiovascular events. As a result, there is no consensus about whose homocysteine levels should be measured and who, if anyone, should receive homocysteine-lowering therapies.

The aim of this paper is to examine whether the evidence is sufficient to recommend homocysteine testing to guide the prevention and treatment of cardiovascular disease, or to recommend using folic acid, vitamin B₆, and vitamin B₁₂ for primary or secondary prevention of cardiovascular disease.

HISTORY OF HOMOCYSTEINE AS A RISK MARKER

Homocysteine is an amino acid formed from the metabolism of methionine, an essential amino acid derived from dietary protein. Although homocysteine was first isolated by Butz and du Vigneaud in 1932,⁶ it was not until 1964 that Gibson et al⁷ reported that patients with homocystinuria (more about this below) had vascular anomalies and arterial thrombosis. In 1969, McCully⁸ made the connection

TABLE 1

Causes of elevated homocysteine

Mild (15–30 $\mu\text{mol/L}$)

Mild-moderate renal disease
 Drug use—antiepileptic drugs, methotrexate, theophylline, niacin, immunosuppressive drugs, fibrates, levodopa, metformin (Glucophage)
 Hypothyroidism
 Hyperproliferative disorders, certain cancers
 Psoriasis
 Methylene tetrahydrofolate reductase (MTHFR) 677C>T variant
 Mild-moderate folate or vitamin B₁₂ deficiency
 Increasing age
 High protein intake
 Low intake of vegetables or fruits
 Sickle-cell anemia

Moderate (30–100 $\mu\text{mol/L}$)

End-stage renal disease
 Moderate vitamin B₁₂ deficiency
 Severe folate deficiency
 MTHFR 677C>T variant combined with low folic acid levels

Severe ($\geq 100 \mu\text{mol/L}$)

Severe vitamin B₁₂ deficiency
 Cystathionine beta-synthase deficiency

BASED ON INFORMATION IN REFERENCES 9, 11, AND 12

between elevated homocysteine levels and the risk of atherosclerosis.

Several possible mechanisms for the association between homocysteine and atherosclerosis have been demonstrated in experimental models. These include stimulation of smooth muscle growth, reduction in endothelial cell growth, impaired endothelial cell relaxation, decreased synthesis of high-density lipoprotein, promotion of autoimmune response, and accumulation of inflammatory monocytes in atherosclerotic plaques.^{3,9,10}

In view of these findings, researchers have been evaluating whether homocysteine-lowering therapies decrease the risk of cardiovascular disease.

CAUSES OF ELEVATED PLASMA HOMOCYSTEINE

An elevated plasma homocysteine level can result from many different factors, including vitamin deficiencies, renal impairment, and inborn errors of homocysteine metabolism (TABLE 1).^{9,11,12}

Vitamin deficiencies. Vitamin B₆ (pyridoxine), vitamin B₁₂ (cyanocobalamin), and folic acid are cofactors required for homocysteine metabolism, and deficiency in any or all of these leads to disruption of the relevant metabolic pathways.

Renal impairment. A low glomerular filtration rate has also been correlated with an elevated plasma homocysteine concentration. This makes sense, since the kidneys perform up to 70% of the clearance of homocysteine, although a cause-and-effect relationship is unclear.¹³

Inborn errors of homocysteine metabolism. *Homocystinuria*, ie, an abnormal elevation of homocysteine in the urine, is caused by several autosomal recessive disorders. People with these genetic variations have extremely high homocysteine levels.

A deficiency in the enzyme cystathionine beta-synthase is quite rare (the incidence in newborn babies has been found to be 1 in 344,000 worldwide and 1 in 65,000 in Ireland and Australia¹⁴), but leads to homocysteine levels greater than 100 $\mu\text{mol/L}$ and often causes cardiovascular disease by the age of 30 years.¹⁵

A deficiency in the enzyme methylene tetrahydrofolate reductase (MTHFR) is a more common cause of mildly to moderately elevated plasma homocysteine levels.¹⁶ The MTHFR deficiency involves a variation at position 677 in the MTHFR gene in which cytosine is replaced by thymidine (thus called C677T or 677C>T).¹⁷ Ten percent of the population are homozygous for this variant (TT), 43% are heterozygous (CT), and 47% are unaffected (CC). Heterozygotes have slightly higher homocysteine levels than unaffected people, while people with the TT genotype have approximately 20% higher homocysteine levels.¹⁷

ELEVATED HOMOCYSTEINE IS COMMON

In a study of a population in Norway from 1992 to 1993, 8.5% had mild elevations in homocysteine (plasma levels 15–29.99 $\mu\text{mol/L}$), 0.8% had moderate elevations (30–99.99 $\mu\text{mol/L}$), and 0.02% had severe elevations ($\geq 100 \mu\text{mol/L}$).^{13,18} The prevalence of hyperhomocysteinemia in the United States

TABLE 2

Studies of homocysteine-lowering dietary factors as primary prevention

| SOURCE | NO. OF PATIENTS | AGE RANGE (YEARS) | WOMEN (%) | VARIABLE OF INTEREST | OUTCOME |
|-------------------------------------|-----------------|-------------------|-----------|--|---|
| Cui et al (2010) ²³ | 58,730 | 40–79 | 61 | Intake of folate, B ₆ , and B ₁₂ | Inverse association between dietary folate and vitamin B ₆ and death from cardiovascular disease (multiple end points) |
| Liu et al (1999) ²⁴ | 75,521 | 38–63 | 100 | Intake of whole grains | Up to 33% lower rate of fatal myocardial infarction (MI), coronary heart disease (CHD), and nonfatal MI (<i>P</i> < .001) |
| Liu et al (2000) ²⁵ | 75,521 | 38–63 | 100 | Intake of whole grains | Up to 51% lower rate of ischemic strokes (<i>P</i> = .003) |
| Merchant et al (2003) ²⁶ | 46,036 | 40–75 | 0 | B-vitamin intake | 21% lower rate of peripheral arterial disease for every 400 μmol/L increase in intake (95% CI 0.64–0.96) |
| Rimm et al (1998) ²⁷ | 80,082 | 30–55 | 100 | Intake of folic acid and vitamin B ₆ | 31% lower rate of nonfatal MI and fatal CHD (95% CI 0.55–0.87) |

is probably much lower, given that supplementation of white flour and cereal grains with folic acid has been mandatory since 1998, but this is not well described in the literature.

■ HOW GREAT IS THE RISK?

Studies over the past 10 to 20 years have shown that elevated homocysteine is a marker of risk of cardiovascular disease. The association was first noted in patients with cystathionine beta-synthase deficiency, who tend to have premature cardiovascular disease.

However, studies of patients with MTHFR 677C>T have yielded mixed results. Although several meta-analyses found up to a 42% higher rate of ischemic heart disease and stroke in patients homozygous for MTHFR 677C>T (the TT genotype) than in those with the CC genotype,^{17,19,20} two other large meta-analyses did not find an association between this variant and vascular risk.^{21,22}

Nonetheless, in a meta-analysis of the association between homocysteine and cardiovascular disease, Wald et al¹⁷ found that for every 5-μmol/L increase in serum homocysteine concentration, the risk of ischemic heart disease increased 20% to 30%.

■ TRIALS OF HOMOCYSTEINE-LOWERING THERAPY HAVE HAD MIXED RESULTS

Primary prevention of cardiovascular disease

Given the finding that treatment with folic acid lowers homocysteine—initially noted in patients with homocystinuria—researchers hypothesized that treatment with folic acid, vitamin B₆, and vitamin B₁₂ would decrease the risk of cardiovascular disease.

Little evidence currently exists to guide recommendations for homocysteine-lowering therapy to prevent first attacks of cardiovascular disease. The few studies published to date have been observational studies of dietary intake (not vitamin supplementation), and many were performed before folic acid fortification was mandated for flour and cereal (TABLE 2).^{23–27} Although the studies suggest that higher B-vitamin intake correlates with less vascular disease and its sequelae, there is uncertainty as to whether it is folic acid, vitamin B₆, or vitamin B₁₂ that is responsible, and also whether supplements would provide the same protective benefit as the presence of these nutrients in a varied diet.

Thus, in its recent evaluation of novel risk markers of cardiovascular disease, the United States Preventive Services Task Force^{28,29} does not recommend measuring the plasma homo-

Researchers have been evaluating whether homocysteine-lowering therapies decrease the risk of cardiovascular disease

TABLE 3

Trials of B-vitamins and folic acid as secondary prevention

| SOURCE | NO. OF PATIENTS | MEAN AGE (YEARS) | MEN (%) | POPULATION | MEAN CHOLESTEROL (MG/DL) | MEAN HOMOCYSTEINE (μmol/L) | BENEFIT |
|--|-----------------|------------------|---------|--|--------------------------|----------------------------|-----------------|
| Albert et al (2008) ⁴ | 5,442 | 63 | 0 | Coronary artery disease or three risk factors for it | Not reported | 12.3 | No |
| Bassuk et al (2004) ⁶¹ | 5,442 | ≥ 40 | 0 | Coronary artery disease or three risk factors for it | To be announced | To be announced | To be announced |
| Bønaa et al (2006) ³⁹ | 2,815 | 63 | 74 | After myocardial infarction | 223 | 13.1 | No |
| SEARCH (2010) ³³ | 12,064 | 64 | 83 | Prior myocardial infarction | Not reported | 13.5 | No |
| Carrero et al (2005) ⁴⁰ | 60 | 63 | 100 | Peripheral vascular disease | Not reported | 13.2 | Yes |
| Ebbing et al (2008) ⁵ | 3,090 | 62 | 80 | After percutaneous coronary intervention | 196 | 11 | No |
| Jamison et al (2007) ⁴⁶ | 2,056 | 66 | 98 | Chronic kidney disease | 167 | 21 | No |
| Khandanpour et al (2009) ³⁶ | 133 | 70 | 68 | Peripheral vascular disease | 170 | 13.3 | Yes |
| Lange et al (2004) ³⁵ | 636 | 61 | 77 | After percutaneous coronary intervention | 198 | 12.6 | No |
| Liem et al (2004) ⁴¹ | 283 | 59 | 70 | Coronary artery disease | 280 | Not reported | No |
| Liem et al (2005) ⁴² | 593 | 65 | 78 | Coronary artery disease | 178 | 12.1 | No |
| Lonn et al (2006) ⁴³ | 5,522 | 69 | 72 | Vascular disease or diabetes mellitus | 186 | 11.8 | No |
| Mager et al (2009) ³² | 492 | 51 | 68 | Premature coronary artery disease, elevated homocysteine | Not reported | 13.2 | Yes |
| Righetti et al (2003) ¹¹ | 81 | 64 | 56 | End-stage renal disease | 199 | 50.3 | No |
| Righetti et al (2006) ³¹ | 88 | 64 | 56 | End-stage renal disease | 196 | 35 | Yes |
| Schnyder et al (2002) ³⁴ | 553 | 63 | 81 | After percutaneous coronary intervention | 213 | 11.3 | Yes |
| Sydow et al (2003) ⁴⁴ | 27 | 67 | 81 | Peripheral vascular disease, elevated homocysteine | Not reported | 15.0 | No |
| Toole et al (2004) ⁴⁵ | 3,680 | 66 | 63 | Cerebrovascular accident | 202 | 13.4 | No |
| Wrone et al (2004) ³⁷ | 510 | 60 | 50 | End-stage renal disease | 184 | 32.9 | No |
| Zoungas et al (2006) ¹² | 315 | 56 | 32 | End-stage renal disease | 201 | 27 | No |

cysteine level in the evaluation of either low-risk or intermediate-risk populations, finding no evidence that it adds any useful information in predicting major coronary events be-

yond what one could get from calculating the Framingham Risk Score. The task force also found no evidence that treating people who have elevated homocysteine levels decreases

their risk of subsequent cardiovascular events.

In addition, a recent Cochrane Database review of eight randomized controlled trials in patients at low risk did not find a lower risk of myocardial infarction (fatal or nonfatal), stroke, or death from any cause in patients receiving B-complex vitamins.³⁰

Secondary prevention of cardiovascular disease

Results have been mixed with regard to the ability of B vitamins to prevent cardiovascular events in patients with known cardiovascular disease (TABLE 3).^{4,5,11,12,31-46}

Bazzano et al,⁴⁷ in a meta-analysis published in 2006, evaluated 12 randomized controlled trials of folic acid supplementation in patients with known cardiovascular disease and did not find that treated patients had better cardiovascular outcomes. The mean homocysteine level was elevated ($> 15 \mu\text{mol/L}$) at baseline in only 4 of the 12 trials. However, in 1 of these 4 trials, there was no difference in outcomes comparing those with and without elevated homocysteine.³¹

Albert et al⁴ more recently evaluated the effect of a combination pill containing folic acid, vitamin B₆, and vitamin B₁₂ on cardiovascular events in women at high risk, ie, those with a history of cardiovascular disease or having three or more coronary risk factors. Treatment did not decrease the rate of the composite outcome of cardiovascular disease mortality, stroke, myocardial infarction, or coronary revascularization, although the homocysteine level decreased by a mean of 30% in the treated group. However, only 27.7% of the participants had an elevated homocysteine level. One might not expect patients to benefit from such treatment if they had normal homocysteine levels to begin with.

Ebbing et al,⁵ in a trial published in 2008, investigated the effect of folic acid, vitamin B₁₂, and vitamin B₆ supplements on the risks of death from any cause and of cardiovascular events in patients undergoing coronary angiography. Outcomes were no better in the treatment group than in the control group, despite a mean decrease in homocysteine level of 19%. However, over 90% of the participants had a normal homocysteine level.

Mager et al,³² in a study published in 2009, looked specifically at whether patients with

coronary artery disease and elevated homocysteine levels ($> 15 \mu\text{mol/L}$) would benefit from folate-based vitamin therapy. In this subset, the incidence of death from any cause was lower in the treated group than in the control group (4% vs 32%, $P < .001$), an association that was not present in patients with normal homocysteine levels.

The **SEARCH trial** (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine),³³ recently published, was a double-blind, randomized controlled trial of vitamin B₁₂ and folic acid treatment in 12,064 patients who had survived a myocardial infarction. Although those who received the vitamin therapy had a 28% reduction in homocysteine level, no clinical benefit was demonstrated. Of note, 66% of the patients had a homocysteine level lower than $14 \mu\text{mol/L}$ at baseline.

Restenosis after angioplasty

Results are also mixed regarding whether folic acid supplements modify the risk of restenosis after coronary angioplasty.

Namazi et al⁴⁸ evaluated the effect of folic acid supplementation on in-stent restenosis in 200 patients and found no difference between the treatment and placebo groups in the rates of either restenosis or target-vessel revascularization.

Schnyder et al⁴⁹ evaluated the effect of folic acid, vitamin B₆, and vitamin B₁₂ treatment on the rate of coronary restenosis (in cases of balloon angioplasty) or in-stent restenosis (if a stent was used). Patients receiving treatment had lower rates of restenosis or in-stent restenosis (40% vs 48%, $P = .01$) and of need for target-vessel revascularization (11% vs 22%, $P = .047$). The mean homocysteine level was not elevated in this study either, and the researchers did not analyze the outcomes according to whether patients had high or normal homocysteine levels.

Lange et al³⁵ also evaluated the effect of folic acid, vitamin B₆, and vitamin B₁₂ treatment on coronary in-stent restenosis. Paradoxically, the rate was higher with treatment in the overall group (mean homocysteine level $12.2 \mu\text{mol/L}$), leading to a higher incidence of target-vessel revascularization. Patients who had a baseline elevation in homocysteine level

43% of people are heterozygous for MTHFR 677C>T; 10% are homozygous

had a nonsignificant trend toward a lower rate of in-stent restenosis.

Cerebrovascular and peripheral arterial disease

The evidence is also mixed for using folic acid and other B vitamins to prevent cerebrovascular disease and peripheral vascular disease. Although a 2007 meta-analysis found that folic acid supplementation decreased the risk of a first stroke by 18% ($P = .045$),⁵⁰ a later meta-analysis contradicts this finding.⁵¹

A 2009 meta-analysis found that patients with peripheral arterial disease had higher homocysteine levels than controls, but it did not find any benefit from supplementation, owing to heterogeneity of the clinical end points used.⁵² Indeed, a 2009 Cochrane Database Systematic Review found that there were no adequate trials of the treatment of patients with peripheral vascular disease who have elevated plasma homocysteine.⁵³

However, immediately after the Cochrane review was published, Khandanpour et al³⁶ published the results of a trial of the effect of folic acid and 5-methyltetrahydrofolate (an active form of folic acid) supplementation on the ankle-brachial pressure index and the pulse-wave velocity in patients with peripheral arterial disease. These measures improved with 16 weeks of treatment. For the ankle-brachial pressure index, the P value was less than .01 for folic acid and .009 for 5-methyltetrahydrofolate; for the pulse-wave velocity, the P value was .051 for folic acid and .011 for 5-methyltetrahydrofolate.

Kidney disease

One could postulate that patients with end-stage renal disease or chronic kidney disease might benefit the most from folic acid supplementation, given the correlation of elevations in homocysteine levels with decline in glo-

merular filtration rate.

However, only one study found a lower rate of cardiovascular events with folic acid supplementation in dialysis patients, and the difference was not statistically significant (25% vs 36%, $P < .08$).³¹ Further, several studies found no benefit of folic acid supplementation in patients with chronic kidney disease.^{11,12,37}

FUTURE DIRECTIONS AND RECOMMENDATIONS

Many experts have suggested that the existing evidence indicates that the homocysteine-lowering therapies folic acid, vitamin B₆, and vitamin B₁₂ do not lower the risk of cardiovascular disease.^{38,54–59} Indeed, the American Heart Association guidelines for cardiovascular disease prevention in women do not recommend folic acid supplementation to prevent cardiovascular disease.⁶⁰ (Recommendations for men are the same as for women.) However, most of the clinical trials have not selected and treated patients with elevated homocysteine levels, but have instead included all patients regardless of homocysteine level.

At least two large ongoing trials are currently evaluating B-vitamin therapy for secondary prevention, but neither trial is looking specifically at patients with elevated homocysteine levels.^{61,62}

Thus, instead of concluding that no patients could benefit from homocysteine-lowering treatment, future studies need to clarify:

- Whether patients with elevated homocysteine would benefit from such treatment
- At what level it would be appropriate to start treatment
- The appropriate target homocysteine level with treatment.

Particularly given the recent finding that folic acid supplementation may increase cancer risk,⁶³ these questions need closer scrutiny. ■

Wald et al:
The risk of
ischemic heart
disease increases
20%–30% with
every 5- μ mol/L
increase in
homocysteine

REFERENCES

1. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. *Mayo Clin Proc* 2008; 83:1203–1212.
2. Boers GH. The case for mild hyperhomocysteinemia as a risk factor. *J Inher Metab Dis* 1997; 20:301–306.
3. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. *Cell Death Differ* 2004; 11(suppl 1):S56–S64.
4. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. *JAMA* 2008; 299:2027–2036.
5. Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. *JAMA* 2008; 300:795–804.
6. Butz LW, du Vigneaud V. The formation of a homologue of cystine by the decompensation of methionine with sulphuric acid. *J Biol*

- Chem 1932; 99:135–142.
7. **Gibson JB, Carson NA, Neill DW.** Pathological findings in homocystinuria. *J Clin Pathol* 1964; 17:427–437.
 8. **McCully KS.** Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am J Pathol* 1969; 56:111–128.
 9. **Zhang D, Jiang X, Fang P, et al.** Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. *Circulation* 2009; 120:1893–1902.
 10. **Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS.** Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. *J Am Coll Cardiol* 1999; 34:2002–2006.
 11. **Righetti M, Ferrario GM, Milani S, et al.** Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. *Med Sci Monit* 2003; 9:PI19–PI24.
 12. **Zoungas S, McGrath BP, Branley P, et al.** Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. *J Am Coll Cardiol* 2006; 47:1108–1116.
 13. **Carmel R, Jacobsen DW, editors.** Homocysteine in Health and Disease. Cambridge, UK: Cambridge University Press, 2001.
 14. **Yap S, Boers GH, Wilcken B, et al.** Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. *Arterioscler Thromb Vasc Biol* 2001; 21:2080–2085.
 15. **McKusick V.** 236200 Homocystinuria. In: McKusick V, editor. Mendelian Inheritance in Man. 10th ed. Baltimore, MD: The Johns Hopkins University Press, 1992:1444–1446.
 16. **McKusick V.** 236250 Homocystinuria due to deficiency of N(5,10)-methylene tetrahydrofolate reductase activity. In: McKusick V, editor. Mendelian Inheritance in Man. Baltimore, MD: The Johns Hopkins University Press, 1992:1447–1448.
 17. **Wald DS, Law M, Morris JK.** Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ* 2002; 325:1202.
 18. **Nygård O, Vollset SE, Refsum H, et al.** Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. *JAMA* 1995; 274:1526–1533.
 19. **Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group.** MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. *JAMA* 2002; 288:2023–2031.
 20. **Kelly PJ, Rosand J, Kistler JP, et al.** Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. *Neurology* 2002; 59:529–536.
 21. **Lewis SJ, Ebrahim S, Davey Smith G.** Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? *BMJ* 2005; 331:1053.
 22. **Brattström L, Wilcken DE, Ohrvik J, Brudin L.** Common methylene tetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. *Circulation* 1998; 98:2520–2526.
 23. **Cui R, Iso H, Date C, Kikuchi S, Tamakoshi A; Japan Collaborative Cohort Study Group.** Dietary folate and vitamin B6 and B12 intake in relation to mortality from cardiovascular diseases: Japan Collaborative Cohort Study. *Stroke* 2010; 41:1285–1289.
 24. **Liu S, Stampfer MJ, Hu FB, et al.** Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. *Am J Clin Nutr* 1999; 70:412–419.
 25. **Liu S, Manson JE, Stampfer MJ, et al.** Whole grain consumption and risk of ischemic stroke in women: a prospective study. *JAMA* 2000; 284:1534–1540.
 26. **Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A.** The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. *J Nutr* 2003; 133:2863–2867.
 27. **Rimm EB, Willett WC, Hu FB, et al.** Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. *JAMA* 1998; 279:359–364.
 28. **US Preventive Services Task Force.** Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force recommendation statement. *Ann Intern Med* 2009; 151:474–482.
 29. **Helfand M, Buckley DI, Freeman M, et al.** Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US Preventive Services Task Force. *Ann Intern Med* 2009; 151:496–507.
 30. **Marti-Carvajal AJ, Solà I, Lathyris D, Salanti G.** Homocysteine lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev* 2009; (4):CD006612.
 31. **Righetti M, Serbelloni P, Milani S, Ferrario G.** Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. *Blood Purif* 2006; 24:379–386.
 32. **Mager A, Orvin K, Koren-Morag N, et al.** Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease. *Am J Cardiol* 2009; 104:745–749.
 33. **Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage JM, Bowman L, Clarke RJ, et al.** Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. *JAMA* 2010; 303:2486–2494.
 34. **Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM.** Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. *JAMA* 2002; 288:973–979.
 35. **Lange H, Suryapranata H, De Luca G, et al.** Folate therapy and in-stent restenosis after coronary stenting. *N Engl J Med* 2004; 350:2673–2781.
 36. **Khandanpour N, Armon MP, Jennings B, et al.** Randomized clinical trial of folate supplementation in patients with peripheral arterial disease. *Br J Surg* 2009; 96:990–998.
 37. **Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP.** Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrol* 2004; 15:420–426.
 38. **Loscalzo J.** Homocysteine trials—clear outcomes for complex reasons. *N Engl J Med* 2006; 354:1629–1632.
 39. **Bonaa KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators.** Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med* 2006; 354:1578–1588.
 40. **Carrero JJ, López-Huertas E, Salmerón LM, Baró L, Ros E.** Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. *J Nutr* 2005; 135:1393–1399.
 41. **Liem AH, van Boven AJ, Veeger NJ, et al; Folic Acid on Risk Diminishment After Acute Myocardial Infarction Study Group.** Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomized pilot trial. *Int J Cardiol* 2004; 93:175–179.
 42. **Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ.** Secondary prevention with folic acid: results of the Goes extension study. *Heart* 2005; 91:1213–1214.
 43. **Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators.** Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* 2006; 354:1567–1577.
 44. **Sydow K, Schwedhelm E, Arakawa N, et al.** ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. *Cardiovasc Res* 2003; 57:244–252.
 45. **Toole JF, Malinow MR, Chambless LE, et al.** Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004; 291:565–575.
 46. **Jamison RL, Hartigan P, Kaufman JS, et al; Veterans Affairs Site**

Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. *JAMA* 2007; 298:1163–1170. Erratum in *JAMA* 2008; 300:170.

47. **Bazzano LA, Reynolds K, Holder KN, He J.** Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *JAMA* 2006; 296:2720–2726.
48. **Namazi MH, Motamedi MR, Safi M, Vakili H, Saadat H, Nazari N.** Efficacy of folic acid therapy for prevention of in-stent restenosis: a randomized clinical trial. *Arch Iran Med* 2006; 9:108–110.
49. **Schnyder G, Roffi M, Pin R, et al.** Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001; 345:1593–1600.
50. **Wang X, Qin X, Demirtas H, et al.** Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. *Lancet* 2007; 369:1876–1882.
51. **Lee M, Hong KS, Chang SC, Saver JL.** Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. *Stroke* 2010; 41:1205–1212.
52. **Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP.** Homocysteine and peripheral arterial disease: systematic review and meta-analysis. *Eur J Vasc Endovasc Surg* 2009; 38:316–322.
53. **Hansrani M, Stansby G.** Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. *Cochrane Database Syst Rev* 2002; (3):CD003285.
54. **Mosca L.** Novel cardiovascular risk factors: do they add value to your practice? *Am Fam Physician* 2003; 67:264, 266.
55. **Anderson JL, Adams CD, Antman EM, et al.** ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. *J Am Coll Cardiol* 2007; 50:e1–e157.
56. **Lonn E.** Homocysteine-lowering B vitamin therapy in cardiovascular prevention—wrong again? *JAMA* 2008; 299:2086–2087.
57. **Milani RV, Lavie CJ.** Homocysteine: the Rubik’s cube of cardiovascular risk factors. *Mayo Clin Proc* 2008; 83:1200–1202.
58. **Bazzano LA.** Folic acid supplementation and cardiovascular disease: the state of the art. *Am J Med Sci* 2009; 338:48–49.
59. **Ntaios G, Savopoulos C, Grekas D, Hatzitolios A.** The controversial role of B-vitamins in cardiovascular risk: an update. *Arch Cardiovasc Dis* 2009; 102:847–854.
60. **Mosca L, Banka CL, Benjamin EJ; Expert Panel/Writing Group.** Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation* 2007; 115:1481–1501.
61. **Bassuk SS, Albert CM, Cook NR, et al.** The Women’s Antioxidant Cardiovascular Study: design and baseline characteristics of participants. *J Womens Health (Larchmt)* 2004; 13:99–117.
62. **SEARCH Study Collaborative Group; Bowman L, Armitage J, Bulbulia R, Parish S, Collins R.** Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. *Am Heart J* 2007; 154:815–823, 823.e1–e6.
63. **Ebbing M, Bønaa KH, Nygård O, et al.** Cancer incidence and mortality after treatment with folic acid and vitamin B12. *JAMA* 2009; 302:2119–2126.

ADDRESS: Leslie Cho, MD, Women’s Cardiovascular Center, JB-1, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail chol@ccf.org.

**Visit our web site at
<http://www.ccjm.org>**

**Contact us by e-mail at
ccjm@ccf.org**



The *Cleveland Clinic Journal of Medicine* uses the AMA’s database of physician names and addresses. (All physicians are included in the AMA database, not just members of the AMA.) **Only the AMA can update this data, and the AMA will accept a change-of-address notice only from you.**

Be sure your primary specialty and type of practice also are up-to-date on AMA records. This information is important in determining who receives the *Cleveland Clinic Journal of Medicine*.

If you have ever notified the AMA that you did not want to receive mail, you will not receive the *Cleveland Clinic Journal of Medicine*. You can reverse that directive by notifying the AMA. Please note that a change of address with the AMA will redirect all medically related mailings to the new location.

FOR FASTER SERVICE

- **PHONE** 800-262-3211 ext. 5192
- **FAX** 312-464-5843
- **E-MAIL** nicole_neal@www.ama-assn.org

or send a recent mailing label along with new information to:

**AMA
 DEPARTMENT OF DATA SERVICES
 515 North State Street
 Chicago, IL 60654**

NEW INFORMATION

NAME _____

STREET ADDRESS _____

CITY _____

STATE _____ ZIP _____

Please allow 6 to 8 weeks for change to take effect